Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06851962
PHASE4

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are: * Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile? * What medical problems do participants experience while taking the treatment? Participants will: * Take the treatment described according to the Summary of Product Characteristics (SmPC). * Visit the clinic once every 12 weeks for checkups and tests. * Keep a diary of their symptoms to inform the Investigator.

Official title: Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.

Key Details

Gender

All

Age Range

40 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

504

Start Date

2025-05-26

Completion Date

2026-06-30

Last Updated

2026-02-23

Healthy Volunteers

No

Interventions

DRUG

Metformin

Metformin maximum daily dose 2000 mg

DRUG

Dulaglutide

Dulaglutide

DRUG

Semaglutide 1.0 mg

Semaglutide

DRUG

Empagliflozin (BI 10773)

Empagliflozin

DRUG

Canagliflozin

Canagliflozin

DRUG

Dapagliflozin

Dapagliflozin

DRUG

pioglitazone

Pioglitazone

DRUG

Sitagliptin

Sitagliptin

DRUG

Vildagliptin (Galvus)

vildagliptin

DRUG

linagliptin

linagliptin

Locations (3)

Hospital Universitario Regional de Málaga

Málaga, Spain

Hospital Clínico Universitario de Valencia

Valencia, Spain

Hospital General Universitario de Valencia (HGUV)

Valencia, Spain